Chemodenervation may help selected patients with orofacial dystonia, jaw spasms, facial muscle overactivity, and related pain patterns.
Orofacial dystonia can cause involuntary muscle contractions that affect the face and jaw. Dr. Siefferman discusses how chemodenervation with botulinum toxin can help reduce symptoms and improve daily function.
Our team organizes conditions and treatments into related zones of expertise to make it easier to explore the care paths most relevant to your symptoms and goals.
Use the zone tags above to browse dedicated pages for each focus area, including services, providers, and what to expect during treatment.
Hi, I’m Dr. Jason Siefferman, medical director at Manhattan Pain Medicine. Chemodenervation is a fancy word for botulinum toxin use, and you may know botulinum toxin as Xeomin or Botox, which are two brand name products which we use for chemodenervation.
In the setting of orofacial dystonia, which means that the jaw closing muscles are hyperactive for no clear reason, there’s increased involuntary tone of the muscle; there’s pain and there’s restricted range of motion using the jaw. In this situation, we can use botulinum toxin to both reduce muscle bulk and weaken the muscles slightly.
Now, the important thing with jaw function is that it must be balanced. If the jaw function is not balanced, we can actually make things worse. So, we very much do not want to do that. We look closely at the mechanics. We look at which muscles are being overused. We want to understand that pattern of use so that we can craft a dosing treatment to optimally rebalance the use of those muscles.
Now the first time we do this, we usually err on the side of undertreatment because we don’t want the jaw to become too weak; otherwise, there can be difficulty chewing, speaking, opening, or closing the jaw. And we let that settle in and then we reevaluate the patient, and if we need to adjust the dose, we do that on future visits.
Chemodenervation for orofacial dystonia is a targeted medical treatment that uses botulinum toxin to temporarily reduce overactivity in selected facial, jaw, mouth, or related muscles. It may be considered for patients with involuntary jaw movements, jaw opening or closing dystonia, facial spasms, painful muscle overactivity, or oromandibular dystonia when clinically appropriate.
At Manhattan Pain Medicine, chemodenervation is not treated as cosmetic Botox or a general facial pain treatment. It begins with a diagnosis-first evaluation to distinguish dystonia from TMJ dysfunction, trigeminal neuralgia, dental pain, headache disorders, and other neurologic or musculoskeletal contributors.
MPM specialists evaluate whether chemodenervation may be appropriate by first identifying the movement pattern, pain source, and muscles involved. Orofacial symptoms can come from dystonia, TMJ dysfunction, jaw clenching, trigeminal neuralgia, dental disease, facial pain syndromes, headache disorders, cervical contributors, or other neurologic conditions.
Chemodenervation may be considered when involuntary or overactive muscles appear to be a meaningful driver of symptoms. The treatment plan requires individualized muscle selection, dose planning, safety review, and realistic expectations, especially because injections around the face, jaw, mouth, and tongue can affect chewing, speech, swallowing, and facial expression.
Orofacial dystonia is different from routine jaw tension or general facial pain. It may involve involuntary contractions, pulling, twisting, jaw deviation, jaw opening, jaw closing, tongue involvement, lower facial spasms, or painful muscle overactivity. Some patients are first treated for TMJ dysfunction, bruxism, headache, dental pain, or trigeminal neuralgia before dystonia is considered.
Chemodenervation uses botulinum toxin to temporarily reduce activity in carefully selected muscles. For the right patient, this may help reduce spasms, involuntary movements, pain related to muscle overactivity, or functional difficulty. However, it does not cure dystonia or replace neurologic evaluation, dental care, TMJ care, headache evaluation, medication management, rehabilitation, or emergency care when those are needed. At MPM, the focus is precise diagnosis, anatomy-driven treatment planning, and coordination with neurology, dentistry, oral surgery, ENT, or headache specialists when appropriate.
Chemodenervation for orofacial dystonia intersects with MPM’s expertise in Musculoskeletal issues and Complex Chronic Pain. Orofacial dystonia can affect muscles involved in chewing, speaking, facial expression, and jaw control. It may also overlap with headache disorders, TMJ dysfunction, trigeminal neuralgia, facial pain, neck pain, or chronic pain sensitivity.
MPM evaluates these overlapping patterns before recommending treatment. Some patients may need coordinated care with neurology, dentistry, oral surgery, ENT, headache specialists, physical therapy, or pain psychology. Others may benefit from targeted botulinum toxin treatment when the dystonia pattern and injection targets are clear. The goal is careful patient selection, precise treatment planning, and realistic expectations.
Before treatment, MPM reviews the diagnosis, involved muscles, injection plan, expected timeline, possible side effects, and safety considerations. During chemodenervation, small amounts of botulinum toxin are injected into selected muscles based on the dystonia pattern. The number and location of injections depend on whether symptoms involve jaw closing, jaw opening, jaw deviation, facial spasm, tongue involvement, or another pattern.
Patients may feel brief pinching, pressure, or soreness. The effect is not immediate and may take days to begin. If benefit occurs, it is temporary and may last weeks to months depending on the patient and treatment plan. Possible side effects include facial weakness, chewing weakness, smile asymmetry, dry mouth, speech changes, swallowing difficulty, or other area-specific effects. Follow-up helps determine whether treatment should be repeated or modified.
I cannot say enough good things about Manhattan Pain Medicine. From the moment I walked in, I felt truly cared for and taken seriously. Dr. Nino Mikaberidze, Director of Rheumatology, is exceptional — knowledgeable, compassionate, and incredibly thorough. She takes the time to listen, explains every...
The best care I've received as a chronic pain patient. I traveled from out of state to visit Manhattan Pain Medicine because I could not find knowledgeable doctors in my hometown for my hypermobility, and Ehlers-Danlos syndrome symptoms and comorbidities. Let me tell you, it was worth every travel e...
I was injured in a bicycle accident over 8 years ago. I’ve suffered throughout the years since my accident with nothing seeming to work. PT, Yoga, lifestyle changes, NOTHNG! I finally made an appointment with Dr Kane and I’m feeling an improvement in my life. I no longer stay up all night in pain, a...
One of the best experiences, if not the best, I have ever had at the doctor’s office. From the front desk to the nurses to the PA assisting the doctor this was a great experience. Dr.Nino actually listened to me and came up with a game plan. Would recommend this practice to as many people as I could...
I have very unique & severe nerve pain from CRPS which has no known specific cure. Dr. Siefferman has a huge tool box, far greater than the other 23 Drs. I have seen. He saved me from jumping off a bridge and continues to help me with both treatments and advice. Dr. S. is in a different league!
After two years of searching and feeling lost and let down, I finally found real help at Manhattan Pain Medicine. With Dr. Siefferman, Adam Rosenberg, Dr. Mikaberidze, and the whole team, I feel heard, supported and understood. Every symptom is being considered and I’m finally getting answers with m...
Why is Dr Dr. Tayyaba Ahmed one of the top pevic Floor specialists - 1- She wants to know a full history of what led the patient to get to this point. 2 - She listens intensley to the patient 3- She does not rush you 4- Extremely skilled at giving pelvic floor injections 5- I thank my luck stars she...
The staff was friendly and helpful. Dr. Siefferman was thoughtful, listened, asked questions and proposed simple safe ways to come to further conclusions regarding my pain and discomfort. The office staff including Dr. Siefferman is responsive even after the initial in-person visit. Very pleased.
Dr. Siefferman is a brilliant provider. While my pain is still a work in progress, Dr Siefferman always gives me options and explains his reasoning behind things. He listens to my feedback and concerns. I never feel rushed; and am grateful he works to meet me where I am. I highly recommend him.
What a great find! They listen to me, I listen to them and the diagnosis is made and a plan developed to develop an approach to treat all of my chronic pain. I wish I could have discovered this type of treatment sooner. This doctor and group give me hope.
Chemodenervation is a medical treatment that uses medication, commonly botulinum toxin, to temporarily reduce activity in selected muscles. In orofacial dystonia, it may be used to target overactive facial, jaw, mouth, or related muscles that contribute to involuntary movements, spasms, pain, or functional difficulty. It is not cosmetic Botox and is not a general treatment for all facial or jaw pain. MPM uses chemodenervation only after evaluating the diagnosis, movement pattern, anatomy, safety factors, and treatment goals.
Orofacial dystonia is a movement disorder that can cause involuntary contractions or abnormal movements of facial, jaw, mouth, tongue, or lower facial muscles. Symptoms may include jaw pulling, jaw opening, jaw closing, jaw deviation, facial spasms, painful muscle overactivity, difficulty chewing, speech changes, or functional limitation. It can sometimes be confused with TMJ dysfunction, bruxism, facial pain, trigeminal neuralgia, or headache-related symptoms. Diagnosis is important because treatment depends on the specific movement pattern and muscles involved.
The terms are related but not always used in exactly the same way. Oromandibular dystonia generally refers to dystonia involving the jaw, mouth, tongue, or lower face, while orofacial dystonia may be used more broadly for dystonia affecting facial and oral regions. Patients may experience jaw closing dystonia, jaw opening dystonia, jaw deviation, tongue involvement, or facial pulling. MPM evaluates the specific pattern rather than relying only on terminology because injection planning depends on which muscles are involved.
Botulinum toxin may help orofacial dystonia by temporarily reducing overactivity in selected muscles. When targeted carefully, this may reduce spasms, involuntary contractions, abnormal jaw movement, or pain related to muscle overactivity. It does not cure dystonia or treat every cause of facial pain. The effect is temporary and varies by patient. MPM uses individualized muscle selection and dosing because the muscles around the jaw, mouth, tongue, and face are important for chewing, speech, swallowing, and expression.
Chemodenervation may help selected patients with jaw spasms or involuntary jaw movements when symptoms are caused by oromandibular dystonia or focal muscle overactivity. This can include jaw closing dystonia, jaw opening dystonia, jaw deviation, or painful jaw muscle contractions. It is not appropriate for every jaw symptom. Jaw pain or movement changes can also come from TMJ dysfunction, dental issues, trigeminal neuralgia, medication effects, headache disorders, or other neurologic conditions. MPM evaluates these possibilities first.
Chemodenervation may be considered for selected facial muscle spasms when overactive or involuntary muscle contractions are contributing to symptoms. The treatment plan depends on which muscles are involved, how the spasms affect function, and whether there are overlapping conditions such as headache, TMJ dysfunction, trigeminal neuralgia, or other neurological concerns. Because injections around the face can affect expression, smile symmetry, speech, and swallowing, MPM plans treatment carefully and sets realistic expectations before proceeding.
Orofacial dystonia is a movement disorder involving involuntary or abnormal muscle contractions. TMJ dysfunction refers to problems involving the jaw joint, chewing muscles, or both. The symptoms can overlap because both may cause jaw pain, tightness, headaches, or difficulty chewing. However, the treatment approach may differ. TMJ dysfunction may require dental care, oral appliances, physical therapy, medication management, or joint-focused treatment. Orofacial dystonia may require neurologic evaluation and targeted chemodenervation when appropriate.
Orofacial dystonia involves involuntary muscle contractions or abnormal movement patterns in the face, jaw, mouth, or tongue. Trigeminal neuralgia is a nerve pain condition that can cause sudden, severe, electric shock-like facial pain. Some patients may have facial pain and muscle reactions, which can make the distinction difficult. MPM evaluates pain quality, triggers, movement patterns, neurological symptoms, and prior diagnoses before recommending treatment. Chemodenervation may help dystonia-related muscle overactivity, but it is not a substitute for neuralgia evaluation or treatment.
Injection sites depend on the dystonia pattern and the muscles involved. Treatment may target selected jaw, facial, mouth, or related muscles depending on whether the patient has jaw closing, jaw opening, jaw deviation, facial pulling, or another pattern. MPM does not select injection sites based only on where pain is felt. The plan is individualized to the movement pattern, anatomy, function, dose, and safety considerations. This careful planning helps reduce the risk of unwanted weakness or functional side effects.
Chemodenervation does not work immediately. Some patients begin to notice changes within several days, while the full effect may take longer depending on the muscles treated, dose, symptom pattern, and individual response. Because orofacial muscles are involved in daily functions such as chewing, speaking, swallowing, and expression, the response must be monitored carefully. MPM reassesses symptom changes, function, and side effects before determining whether treatment should continue or be adjusted.
The effect of chemodenervation is temporary. If treatment helps, benefit may last weeks to months depending on the patient, dose, muscles treated, and response. Symptoms may gradually return as the medication effect wears off. Repeat treatment may be considered at medically appropriate intervals after reassessment. MPM reviews whether spasms, involuntary movements, pain, chewing, speech, swallowing, and facial function improved before deciding whether another treatment cycle is appropriate.
Repeat timing depends on the diagnosis, treatment response, side effects, duration of benefit, and medical judgment. Many botulinum toxin-based treatments are repeated only after the prior effect has worn down and reassessment confirms that treatment remains appropriate. MPM does not repeat injections automatically. The team reviews symptom response, function, muscle targets, dose, and adverse effects before deciding whether to continue, modify, or stop treatment.
Risks may include injection-site pain, bruising, facial weakness, chewing weakness, jaw fatigue, smile asymmetry, dry mouth, speech changes, swallowing difficulty, aspiration risk, breathing difficulty, allergic reaction, or spread of toxin effect. Risk depends on the muscles treated, dose, anatomy, and patient-specific factors. Extra caution is needed for patients with neuromuscular junction disorders, significant swallowing or breathing problems, active infection at injection sites, pregnancy or breastfeeding considerations, medication interactions, or prior reaction to botulinum toxin.
Chemodenervation may not be appropriate when the diagnosis is unclear, symptoms are not driven by muscle overactivity, or safety risks outweigh potential benefit. It may need to be avoided or delayed with active infection at injection sites, certain neuromuscular conditions, significant swallowing or breathing problems, medication concerns, pregnancy or breastfeeding considerations, or prior serious reaction to botulinum toxin. Urgent evaluation is needed for trouble breathing, trouble swallowing, severe allergic reaction, sudden facial droop, new neurological deficits, severe jaw locking, fever, facial swelling, dental infection symptoms, sudden severe headache, vision changes, chest pain, or rapidly worsening symptoms.
Before care begins, our team helps patients understand the practical side of treatment, including insurance verification, out-of-network benefits, cost-share estimates, self-pay options, and billing questions. We believe patients should have as much clarity as possible before moving forward.
Chemodenervation for orofacial dystonia is a targeted medical treatment that uses botulinum toxin to temporarily reduce overactivity in selected facial, jaw, mouth, tongue, or related muscles. It may be considered for patients with involuntary jaw movements, facial spasms, jaw deviation, jaw closing dystonia, jaw opening dystonia, painful muscle contractions, or oromandibular dystonia.
At Manhattan Pain Medicine (MPM), chemodenervation for orofacial dystonia NYC care begins with diagnosis. Not all jaw pain, facial pain, headache, muscle tightness, or TMJ symptoms are dystonia. The goal is to identify whether a true movement disorder or focal muscle overactivity is contributing to the patient’s symptoms before recommending injections.
Orofacial dystonia refers to abnormal or involuntary muscle contractions affecting parts of the face, jaw, mouth, or related regions. Oromandibular dystonia often refers more specifically to dystonia involving the jaw, lower face, mouth, or tongue. Symptoms may include involuntary jaw closing, jaw opening, jaw deviation, tongue movement, facial pulling, spasms, pain, difficulty chewing, speech changes, or functional limitation.
Patients may search for treatment for facial and jaw muscle spasms after being told they have TMJ dysfunction, bruxism, facial pain, trigeminal neuralgia, or chronic headache. These conditions can overlap, but they are not the same. Orofacial dystonia is primarily a movement disorder, and treatment must be based on the movement pattern.
Chemodenervation uses botulinum toxin to temporarily reduce nerve signaling to selected muscles. When properly targeted, it may reduce involuntary contractions, spasms, overactivity, or pain related to dystonic muscle activity. It does not cure dystonia or eliminate all facial pain. The effect is temporary, and response varies.
Because the muscles of the jaw, face, mouth, and tongue are involved in chewing, speech, swallowing, facial expression, and airway protection, treatment requires careful planning. The goal is to reduce unwanted overactivity while minimizing functional side effects such as chewing weakness, speech changes, swallowing difficulty, smile asymmetry, or facial weakness.
Orofacial dystonia and TMJ dysfunction can both cause jaw pain, tightness, headaches, and difficulty chewing. TMJ dysfunction may involve the jaw joint, chewing muscles, dental factors, disc problems, arthritis, clenching, or bruxism. Orofacial dystonia involves involuntary or abnormal muscle activation.
This distinction matters because Botox for TMJ-related muscle pain and chemodenervation for jaw dystonia Manhattan care may involve different targets, dosing, expectations, and coordination. A patient with primarily joint-driven TMJ pain may need dental care, oral appliance therapy, physical therapy, anti-inflammatory treatment, joint evaluation, or other care. A patient with oromandibular dystonia may need neurology input and targeted botulinum toxin injections.
Facial pain can also come from trigeminal neuralgia, migraine, tension headache, cluster headache, hemicrania, trigeminal autonomic cephalalgias, dental disease, sinus disease, or cervical contributors. Trigeminal neuralgia often causes sudden, severe, electric shock-like facial pain. Headache disorders may cause head, face, jaw, or neck symptoms. Dystonia typically involves involuntary muscle activity or abnormal movement patterns.
MPM evaluates pain quality, triggers, movement patterns, neurological symptoms, headache features, dental history, and prior treatment response before recommending chemodenervation. If symptoms suggest neuralgia, headache disorder, infection, dental disease, or another neurological condition, additional evaluation may be needed.
MPM identifies the muscles most likely contributing to the dystonia pattern. This may vary depending on whether symptoms involve jaw closing, jaw opening, jaw deviation, tongue involvement, facial pulling, or lower facial spasms. Injection targets and dosing are individualized. In some cases, coordination with neurology, dentistry, oral surgery, ENT, or headache specialists may be recommended.
Treatment is not judged only by pain reduction. MPM also considers chewing, speech, swallowing, facial expression, movement control, headaches, functional ability, and side effects. If the first treatment does not provide enough benefit, the plan may be adjusted after reassessment. If symptoms suggest another diagnosis, the care pathway may change.
Risks of chemodenervation around the face and jaw include injection-site pain, bruising, facial weakness, chewing weakness, smile asymmetry, dry mouth, speech changes, swallowing difficulty, aspiration risk, breathing difficulty, allergic reaction, and spread of toxin effect. These risks make precise dosing and muscle selection especially important.
Extra caution is needed for patients with neuromuscular junction disorders, significant swallowing or breathing problems, active infection at injection sites, pregnancy or breastfeeding considerations, medication interactions, or prior reaction to botulinum toxin. Patients should seek urgent evaluation for trouble breathing, trouble swallowing, severe allergic reaction, rapidly worsening weakness, sudden facial droop, new neurological deficits, severe jaw locking, fever, facial swelling, dental infection symptoms, sudden severe headache, vision changes, chest pain, or rapidly worsening symptoms.
For selected patients, chemodenervation may be a useful treatment for orofacial dystonia. MPM’s role is to determine whether dystonia is truly present, identify the right muscle targets, set realistic expectations, and coordinate treatment within the patient’s broader pain and neurologic care plan.
